Skip to main content
. 2017 Oct 24;17(1):79–86. doi: 10.3892/mmr.2017.7859

Figure 3.

Figure 3.

Quantification of RGS5 immunoreactivity. The expression of RGS5 at days 4 and 6of rh-ES-treated Lewis lung cancer tumors demonstrated a significant reduction compared with NS LLC tumors, whilst there was no significant difference at days 2 and 9 between the two groups. *P<0.05 vs. NS. RGS5, regulator of G-protein signaling 5; rh-ES, recombinant human endostatin; NS, normal saline.